We’re at EASL Congress 2026!
We’re excited to be at the European Association for the Study of the Liver (EASL) Congress 2026, Europe’s largest event dedicated to liver health where doctors, scientists, allied health professionals, patients, and industry partners come together to share knowledge, highlight scientific breakthroughs, and build meaningful connections.
Our presence at EASL Congress 2026 reflects our continued commitment to driving progress in rare liver diseases. Through six scientific presentations – including three late‑breaking posters – expert‑led symposia and Meet the Expert sessions, we are contributing to the advancement of science and supporting meaningful conversations about improvements in patient care.
At Ipsen, rare liver diseases are a core focus of our portfolio. We apply our scientific expertise across five rare cholestatic liver diseases: primary biliary cholangitis (PBC), progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS), biliary atresia (BA), and primary sclerosing cholangitis (PSC).
Through our clinical development programs, we aim to advance scientific understanding of rare liver diseases and their impact on the people who live with them. As these conditions can present in unpredictable ways, personalized management is essential, not only to control disease progression but also to address the symptoms that matter most to people living with a rare liver disease.
Outcomes improve when people living with a rare liver disease understand their condition, and when they are active partners in ongoing goal setting and reviews with their healthcare teams.
A collaborative, holistic approach means bringing together patients, carers, and multidisciplinary professionals, who listen to each other and understand the impact of diseases, including life impacting symptoms such as fatigue and pruritus. This will ensure that management plans reflect clinical priorities while fully accounting for the realities of living with a rare liver disease.
Learning more about PBC and Fatigue
An exciting development at this year’s EASL Congress 2026, is the increased recognition of the need to assess and actively manage fatigue in PBC due to its significant burden.
Fatigue in PBC is far more than just being tired; it is a distinct, debilitating clinical symptom that fundamentally alters a person’s quality of life. It is a profound, persistent lack of energy that forces difficult daily choices, impacting everything from physical movement and cognitive function to emotional and social well-being. By affecting even the simplest tasks and personal interactions, PBC-related fatigue necessitates a dedicated approach to care.
Discover more about the reality of living with PBC fatigue here.
Seeing our data spark discussion and recognizing its potential to influence real‑world care reinforced an important truth: our science is driven by purpose
Olivia Brown, EVP, Head of Neuroscience
There are moments that stay with you. Not because of a single slide or headline, but because you can feel something changing. Expectations shift. Standards rise. A new chapter begins.
That is what SCALE represented this year: it signalled the directions where aesthetic medicines is heading. Aesthetic medicine is evolving beyond surface‑level outcomes. Physicians increasingly seek treatments grounded in evidence, developed with intention, and delivered to consistently high standards.
For Ipsen, this moment also matters. We are not new to aesthetics. For decades, our development in neuroscience has spanned both therapeutic and aesthetic indications, supported by deep experience in complex biologics and high‑quality manufacturing. Our medicines are approved for aesthetic use in more than 80 countries worldwide, through our direct presence and trusted partners.
What differentiates companies in this field is their approach and execution.
Aesthetics addresses individual patient needs. Behind every treatment decision is a human story: a change in life, confidence, identity, or sense of self. People are looking for a quality of life, not solely an aesthetic enhancement.
That is why the future of aesthetics will be shaped by a more intentional standard, one that respects the individual, values consistency and predictability, and recognizes the responsibility that comes with developing, manufacturing and delivering these treatments.
At Ipsen, we follow the science and let data guide our decisions. This principle extends beyond research. It means refusing shortcuts, designing with purpose and committing to quality at every step – from development through to manufacturing.
SCALE marked that shift. Not just a congress, but a point in time that reflects the direction the aesthetics industry is taking and the standards the community expects. It was also a milestone for Ipsen, as our role in aesthetics became more visible.
For me personally, this moment carries added significance. Since joining Ipsen I found a sharper awareness of the moments that shape not just careers, but responsibility for the standards we set and the trust we earn. SCALE was one of those moments.
A reminder that aesthetics is entering a more considered, more intentional era – one where scientific rigour, quality and standards matter as much as outcomes. And one where how we innovate is just as important as what we create.
Ipsen’s 2025 Integrated Annual report report is now available on Ipsen.com. This essential reference document brings together key information and insights into the major developments in 2025 and what lies ahead.
This year’s report offers a clear view of how our strategy, ‘Focus. Together. For patients & society,’ has translated into progress through our business performance, pipeline advancement, culture, sustainability and, above all, impact for patients, since its launch in 2020.
“Guided by our strategy, we have embarked on exciting new partnerships, expanded our pipeline and portfolio and shared promising data from our clinical trials. All of this broadened the range of options for patients living with difficult-to-treat conditions in oncology, rare disease and neuroscience,” says David Loew, CEO.
Read David Loew’s Q&A for additional insights on the progress achieved and the priorities ahead, or download the full report.
“All medicines have side effects, but it’s just about trying to minimize the impact through providing the information patients and clinicians need or finding other ways to mitigate that impact.” — Jacintha Sivarajah
With over 15 years of experience in the pharmaceutical industry, Jacintha now leads safety oversight for developing medicines. “My role is not only to ensure a proactive safety strategy but also, together with my Global Patient Safety colleagues, to provide robust safety surveillance for all patients enrolled across the whole program.”
She also sees safety science as a way of maintaining the crucial balance between risk and benefit. “What I do is help to ensure that whatever we do—whether it’s in our clinical trial programs or looking after the safety reporting when people report side effects—we assess that against the benefits and risks of treatments,” she says. “We aim to ensure that the benefit–risk balance remains in favor of the patients taking them.”
That balance requires vigilance and evolving tools. “Signal detection is a really important part of what we do in safety,” she explains. “You’re looking to see whether there are patterns emerging in side effects and whether that is associated with our medicine or not.” For Jacintha, the science of safety is about putting patients first.
“Ultimately, we all work to focus on the well-being of patients,” she says. “That’s what drives us all.”
Christelle Huguet, EVP Head of R&D
Ipsen is not new to aesthetics. For more than three decades, we have been advancing neuroscience innovations across therapeutic and aesthetic indications, building deep expertise in complex biologics, rigorous clinical development and high‑quality manufacturing. Our approved medicines are approved for aesthetic use in more than 80 countries worldwide, through our direct presence and trusted partners.
This heritage matters because the field of aesthetics is evolving, and its future will be shaped by science and data.
At Ipsen, innovation has always followed understanding. We build on what we know, learn from data and apply the same scientific discipline across therapeutic and aesthetic medicine. That approach has allowed us to translate decades of neuroscience research into solutions designed to meet rising expectations around quality, consistency and clinical robustness.
Today, expectations are changing. Patients, consumers and their treating physicians want treatments grounded in evidence, designed with intention and developed to consistently high standards. That requires more than incremental iteration, it demands deep biological insight, rigorous development pathways and confidence in the science behind every decision.
This conviction is reflected in how we invest. Today, 15% of Ipsen’s total R&D investment is dedicated to aesthetic indications.* We are advancing multiple Phase II and Phase III studies across aesthetic uses, reinforcing our vision to remain the engine of meaningful innovation in aesthetics.
Science‑led innovation also depends on the ability to translate discovery into reality. Ipsen’s manufacturing facilities are equipped with capabilities designed for the next generation of complex biologic treatments. They reflect long‑term investment in quality, reproducibility and manufacturing excellence – capabilities that matter when science moves from hypothesis to patient.
Aesthetics is advancing rapidly. But progress that lasts is built on evidence, experience and execution.
At Ipsen, we continue to shape the future of aesthetics through evidence based research, data driven decisions and building on decades of neuroscience expertise to deliver innovation.
*Reflects Ipsen R&D spend projected for 2026. Internal figure, February 2026.
We have delivered a strong start to 2026, reporting total sales growth of 22.6% at constant exchange rates in the first quarter. The performance reflects solid execution across our core therapeutic areas and continued demand for our differentiated medicines.
The Q1 results underscore our focus on delivering meaningful innovation for patients while driving sustainable, long‑term growth.
Consistent growth across all core therapeutic areas
Our first‑quarter performance was supported by balanced growth across Oncology, Rare Disease, and Neuroscience, driven by the strength and diversification of our portfolio.
- Oncology sales increased by 13.0%, with by continued strong demand across key brands and markets.
- Rare Disease recorded exceptional growth of 125.4%, reflecting successful commercialization efforts and increasing patient access to Ipsen’s rare disease treatments.
- Neuroscience sales grew by 18.5%, supported by sustained underlying demand and effective commercial execution.
This performance demonstrates our ability to deliver growth across multiple therapeutic areas addressing high unmet medical needs.
Well positioned for the year ahead
We’re starting 2026 with momentum and confirmed our 2026 full-year guidance. Looking ahead, we remain focused on advancing our pipeline, supporting launches, and reinforcing our position in Oncology, Rare Disease, and Neuroscience.
* All figures at constant exchange rates.
Sandra Silvestri, M.D., PhD, Executive Vice President and Chief Medical Officer, Ipsen.
For the hundreds of children diagnosed with pediatric low-grade glioma (pLGG) across Europe each year, the journey is rarely what families expect. It is often long, complex, and life-altering. However today, we’re excited that the treatment landscape has progressed.
The European Commission (EC) has granted conditional marketing authorization for the first targeted therapy in Europe for children with relapsed or refractory pLGG, irrespective of the type of BRAF alteration.
As a physician, I have seen how heavily uncertainty can weigh down the families of children with life-altering conditions. With pLGG, it is not just a medical challenge. It can be a lifelong one. For these families, this approval represents something genuinely new: a treatment option developed specifically for the biology of pLGG.
pLGG is a rare and life-altering brain tumor that can cause profound and lasting neurological consequences – loss of vision, speech difficulties, learning challenges – all of which shape a child’s development and quality of life well into adulthood. Treatment frequently involves surgery and repeated chemotherapy, with limited options if the disease returns.
At a time when only a small fraction of new medicines focus on pediatric diseases, this approval marks a rare but important advance in pediatric oncology.
The EC approval reflects the collective effort of researchers, clinicians, trial participants, patient advocates, and Ipsen teams who have worked with a singular focus on this disease. I am deeply grateful to each of them.
But approval is just the beginning. Our focus now turns to ensuring this therapy reaches the children and families across Europe who need it. We stand ready to work collaboratively with stakeholders across member states to support timely access.
Children living with rare cancers deserve more options. To them, and to the families who have never stopped hoping: we will keep going.
In the pharmaceutical industry, it’s easy to focus on data, strategy, and performance metrics. But behind every decision are real people. For Guillermo Castillo Acero, Head of European Mid-Sized Markets at Ipsen, that reality became clear during a precise moment in his career.
Early on, Guillermo describes his role as driven largely by delivering results. That changed during an awareness campaign on spasticity, organized in partnership with a patient association. The initiative, a race designed to raise visibility and promote inclusion, brought together patients, families, and healthcare stakeholders around a shared cause.
During a disease awareness event, Guillermo had the chance to speak directly with families. He expected conversations about treatments or clinical outcomes. Instead, what he heard was far more personal. They spoke about everyday challenges, getting dressed, eating, managing routine tasks, things often overlooked but deeply impactful for people living with spasticity.
The experience was emotional. Guillermo recalls struggling to hold back tears as he watched families connect, share, and find joy simply in being part of a supportive community. That moment stayed with him and reshaped how he viewed his work, not as a business responsibility, but as something that directly affects lives, both for patients and those around them.
Since then, Guillermo approaches his role with a stronger sense of purpose. The work is no longer just about outcomes on paper, it’s about enabling better daily lives. Sometimes, it only takes one moment to change how we see what we do. For Guillermo, it was listening, truly listening, to patients and their families, and realizing the human impact behind every decision.
By Christelle Huguet, EVP & Head of R&D, Ipsen
For too long, modern medicine has treated diseases as if they were uniform, defined by a label rather than by their underlying biology. Today, we have an unprecedented ability to interrogate the molecular drivers that shape each person’s cancer, and in doing so, we’re transforming how we diagnose, develop and deliver the medicines that matter most.
At the heart of this transformation lie biomarkers. What mutations are driving disease progression? How do tumor cells distinguish themselves from healthy cells? And importantly, how can these biological signatures guide us to the people with the highest unmet need? The ability to answer these questions allows us to focus our efforts on the most compelling science—science with purpose.
However, biomarkers are only one part of the story. As we unlock deeper insights into disease mechanisms, we must also equip ourselves with the right tools to act on them. That is why Ipsen is building a multimodality R&D engine, grounded in precision immune‑modulation and our expertise in the MAPK pathway. Each modality is designed with purpose: to act on well‑defined biology as a potential best‑ or first‑in‑class medicine.
What makes this progress truly powerful is its real‑world impact on patients. It opens doors to more targeted, and potentially more effective, options. But it’s equally important to recognize where the pathophysiology drivers are less clear and more work is required. Many cancers lack clear biomarkers, and too many patients continue to face conditions that remain under researched or poorly understood. This is exactly why we must continue to push the boundaries of innovation—so that scientific progress translates into real change.
At Ipsen, our ambition is clear: to develop a pipeline defined not by the limits of traditional medicine development, but by the possibilities of precision. Precision medicine is not a new concept—it is here, reshaping what we can deliver for patients today and redefining what will be possible for generations to come. And as science advances, we will continue to act with agility, focus and purpose to turn breakthrough insights into real solutions for the people who need them most.
“To succeed at this, you need to have some tolerance for failure and risk taking.”
At the heart of Ipsen’s early discovery efforts is a question of fit—how a molecule interacts with a disease-relevant protein, and what that means for therapeutic potential. Alexis Cocozaki’s team focuses on that exact space, applying biophysical and structural biology techniques to evaluate and optimize new assets at the atomic level.
“We isolate specific protein targets and run in vitro biochemical assays to identify molecules that inhibit those targets,” Alexis explained. Once a compound shows promise, they move into structural validation. “We determine the structure of the protein bound to the molecule to help guide the chemists in how to improve it.”
This work is foundational to structure-based drug design and early asset triage. By the time a compound reaches exploratory development, much of the molecular logic has already been built. “It’s about reducing uncertainty early—so later-stage teams can move with confidence.”
Early on, Alexis worked in hospital diagnostics—processing patient samples, analyzing infections, and generating data. That clinical exposure gave him a lasting sense of urgency. “It made me want to understand what was really going on at the molecular level. That’s where change begins.”
Structural biology, he believes, is undergoing its own shift. Tools for predicting protein structures, and the collective resource of artificial intelligence are beginning to accelerate a field once defined by months of trial and error. “The idea that we could pool together all of what’s out there into collective open source resources to help guide us on what we should focus on next will keep the industry moving forward at a fast pace.”
Through his efforts to anchor structure in strategy, Alexis is helping shape Ipsen’s approach to precision discovery—where insight builds momentum, and every atom mapped is a step toward what matters next.